Rationale: The first DOACs have been approved for treatment of thromboembolism in children. Based on the risk benefit profiles published so far, we expect DOACs to be widely used in children. The strict inclusion criteria for participation in the RCTs limit their generalizability, particularly to those with serious medical conditions that account for a significant … Continue reading Throm-PED registry: Thrombosis of the hepatic vessels incl. Portal Vein thrombosis and Hepatic vein thrombosis with or without underlying liver disease